Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 980147, 8 pages
Clinical Study

Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study

1Universidad de Colima, 28046 Colima, COL, Mexico
2Centro Universitario de Tonala, Universidad de Guadalajara, 48525 Tonala, JAL, Mexico
3Centro Universitario de Ciencias de la Salud (CUCS), Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
4Departamento de Inmunología, Facultad de Medicina, Universidad Autonoma de Guadalajara, 44670 Guadalajara, JAL, Mexico
5Centro Universitario de Investigacion Biomedica, Universidad de Colima, 28040 Colima, COL, Mexico
6Coordinación de Investigacion, Division de Cirugia, Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, 44280 Guadalajara, JAL, Mexico
7Instituto de Investigación en Reumatologia y del Sistema Musculoesqueletico, CUCS, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
8Hospital General Regional No. 110, Instituto Mexicano del Seguro Social (IMSS), 44716 Guadalajara, JAL, Mexico
9Unidad de Investigacion en Epidemiologia, Clinica, Hospital de Especialidades Centro Medico Nacional de Occidente (CMNO), IMSS, 44340 Guadalajara, JAL, Mexico
10Departamento de Fisiologia, CUCS, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
11División de Genetica, Centro de Investigacion Biomedica de Occidente, IMSS, 44340 Guadalajara, JAL, Mexico
12Instituto de Genetica Humana, CUCS, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico
13División de Investigacion en Salud, UMAE, CMNO, IMSS, 44340 Guadalajara, JAL, Mexico
14Facultad de Medicina, Decanato de Ciencias de la Salud, Universidad Autonoma de Guadalajara, 44670 Guadalajara, JAL, Mexico
15Servicio de Medicina Interna, Inmunologia y Reumatologia, Hospital General de Occidente, Secretaria de Salud Jalisco, 45170 Zapopan, JAL, Mexico

Received 19 September 2014; Revised 30 December 2014; Accepted 6 January 2015

Academic Editor: Clelia M. Riera

Copyright © 2015 Alberto Daniel Rocha-Muñoz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To evaluate the effect of anti-TNF agents plus synthetic disease modifying antirheumatic drugs (DMARDs) versus DMARDs alone for ankylosing spondylitis (AS) with reduced pulmonary function vital capacity (FVC%). Methods. In an observational study, we included AS who had FVC% <80% at baseline. Twenty patients were taking DMARDs and 16 received anti-TNF + DMARDs. Outcome measures: changes in FVC%, BASDAI, BASFI, 6-minute walk test (6MWT), Borg scale after 6MWT, and St. George’s Respiratory Questionnaire at 24 months. Results. Both DMARDs and anti-TNF + DMARDs groups had similar baseline values in FVC%. Significant improvement was achieved with anti-TNF + DMARDs in FVC%, at 24 months, when compared to DMARDs alone (). Similarly, patients in anti-TNF + DMARDs group had greater improvement in BASDAI, BASFI, Borg scale, and 6MWT when compared to DMARDs alone. After 2 years of follow-up, 14/16 (87.5%) in the anti-TNF + DMARDs group achieved the primary outcome: FVC% ≥80%, compared with 11/20 (55%) in the DMARDs group (). Conclusions. Patients with anti-TNF + DMARDs had a greater improvement in FVC% and cardiopulmonary scales at 24 months compared with DMARDs. This preliminary study supports the fact that anti-TNF agents may offer additional benefits compared to DMARDs in patients with AS who have reduced FVC%.